NCT04840550View on ClinicalTrials.gov

Study to Evaluate the Safety, Efficacy of Tegoprazan for the Prevention of PUD in Patients on Treatment With NSAIDs

PHASE3UnknownINTERVENTIONAL
Enrollment

390

Participants

Timeline

Start Date

May 7, 2021

Primary Completion Date

June 30, 2024

Study Completion Date

July 31, 2024

Conditions
Preventive Peptic Ulcer
Interventions
DRUG

Lansoprazole 15 mg

Lansoprazole 15 mg tablets will be orally administered once a day, with NSAIDs, for up to 6 months.

DRUG

Tegoprazan 25 mg

Tegoprazan 25 mg tablets will be orally administered once a day, with NSAIDs, for up to 6 months.

Trial Locations (2)

Unknown

RECRUITING

Samsung Medical Center, Seoul

RECRUITING

The catholic univ. of Korea Eunpyeong ST. Mari's hospital, Seoul

Sponsors
All Listed Sponsors
lead

HK inno.N Corporation

INDUSTRY